Serum microRNA 15a and its clinical implication on type 2 diabetic patients / (Record no. 176649)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 08060namaa22004571i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251213105613.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251211s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.462 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.462 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.11.18.Ph.D.2025.Sa.s |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Sara Abdelrahman Ali Asal, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Serum microRNA 15a and its clinical implication on type 2 diabetic patients / |
| Statement of responsibility, etc. | by Sara Abdelrahman Ali Asal ; Supervised Prof. Dr. Noha Taha Abd-Elraheem, Dr.Rasha sobh Mohamed Farag, Dr. Noran Atef Elkordy, Prof. Dr. Amal Ahmed Mohamed. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | نسبة الميكرو ار ان ايه 15 أ في الدم واثارها السريريه علي المرضي المصابين بداء السكري من النوع الثاني |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 111 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 78-109. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Type 2 Diabetes (T2D) is one of the most common chronic diseases worldwide, and it is estimated that 537 million adults aged 20–79 years are currently living with diabetes. This represents 10.5% of the world’s population in this age group the total number is predicted to rise to 643 million (11.3%) by 2030 and to 783 million (12.2%) by 2045 (Magliano et al., 2021).Chronic elevation in blood glucose levels in type 2 diabetes (T2D) increases macrovascular complications including cardiovascular diseases (CVDs) such as atherosclerosis, myocardial infarction, stroke, and microvascular complications such as nephropathy, neuropathy and retinopathy. These complications lead to significantly increased morbidity and mortality (Forbes et al., 2013). There are no biomarkers for predicting T2D, and the currently available blood glucose tests serve as diagnostic rather than predictive tools (Dehghani et al., 2020).<br/>Aim of work: To study the association between microRNA 15a and type 2 diabetes mellitus and the possibility of being a predictor and biomarker for type 2 diabetes mellitus.<br/>Patients and Methods: A total of 25 diabetic patients, 25 prediabetic patients and 25 apparently healthy control subjects were enrolled. All subjects were subjected to detailed history taking and thorough clinical examination including anthropometric measures (Body mass index (BMI) and waist circumference). Laboratory work-up included complete blood count (CBC), lipid profile (total cholesterol, low density lipoprotien (LDL), high density lipoprotien (HDL), triglycerides), serum transaminases (AST, ALT), serum urea and creatinine levels, serum fasting blood sugar, 2hours postprandial and glycated hemoglobin (HbA1C). Measurement of serum microRNA 15a level using Reverse Transcription- Polymerase Chain Reaction.<br/>Results: Serum microRNA15a level was lower among diabetic group (0.68 ±0.30) as compared to prediabetic and normal control, there was a statistically significant difference between control and diabetic patients (p-value <0.05), on the other hand there was non-statistically significant difference between healthy controls and pre-diabetic and between pre-diabetic and diabetic patients. Using ROC curve analysis, the sensitivity and specificity of microRNA 15a serum level for prediction of DM conditions in the current study was evaluated: a microRNA 15a serum level of ≤1.03 could predict DM with a sensitivity of 92% and a specificity of 68%<br/>Conclusion: The current study investigated the association between micro-RNA 15a and type 2 diabetes mellitus and the possibility of being a biomarker for type 2 diabetes mellitus. The expression patterns of miRNA-15a for possible discernment among T2D, pre-diabetes, and healthy subjects. The results revealed different expression patterns for miRNA-15a in Egyptian population, which can be considered as a valuable cornerstone for upcoming studies on the biomarker capability of these microRNAs for T2D. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | يُعرف مرض السكري بأنه متلازمة، وهي مجموعة من الاضطرابات التي تتميز بفرط سكر الدم وعدم تحمل الجلوكوز، إما بسبب نقص الأنسولين أو ضعف فعالية عمل الأنسولين، أو بسبب مزيج من هذه الأسباب.<br/>للأسف، لا يوجد علاج لمرض السكري حتى الآن، ولكن من خلال التحكم في مستويات السكر في الدم من خلال اتباع نظام غذائي صحي وممارسة الرياضة والأدوية، يمكن تقليل خطر حدوث مضاعفات مرض السكري على المدى الطويل.<br/>البيانات المتعلقة بوباء مرض السكري في مصر نادرة. ومع ذلك، وفقًا للاتحاد الدولي للسكري، تحتل مصر المرتبة التاسعة في انتشار مرض السكري على مستوى العالم، وكان عدد مرضى السكري البالغين 8،850،400 في أوائل عام 2020، مع انتشار بنسبة 15.2٪.<br/>تم التعرف علىالميكرو ار ان اي (miRNAs)لأول مرة في عام 1993، ويمثل هذا الحمض النووي، إلى جانب الحمض النووي الريبوزي غير المشفر (lncRNAs) والحمض النووي الريبوزي الدائري (circRNAs)، أكثر من 98.5% من إجمالي الجينوم البشري.<br/>الميكرو ار ان اي (miRNAs) عبارة عن حمض نووي ريبوزي غير مشفر (ncRNAs) شديد الحفظ بحجم صغير يبلغ حوالي 22 قاعدة نوكليوتيد في الطول. تتمثل الوظيفة الرئيسية لـmiRNANفي تنظيم ما يقرب من 60% من التعبير الجيني المشفر للبروتين على مستوى ما بعد النسخ، وبالتالي فهو يشارك في العديد من العمليات الخلوية المختلفة مثل الانتشار والتمايز والاستماتة.<br/>علاوة على ذلك، نظرًا لمشاركتها في عمليات بيولوجية متعددة، تعتبر الميكرو ار ان اي بمثابة علامات بيولوجية سريرية وأهداف علاجية للعديد من الأمراض.<br/>في العقود الماضية، تمت دراسة ملف تعريف الميكرو ار ان ايعلى نطاق واسع في كل من الدم وجزر البنكرياس، مما يدل على أن علامة التغيير في الميكرو ار ان ايمتورطة في سياق مرض السكري.<br/>الهدف من دراستنا هو دراسة العلاقة بين الميكرو ار ان اي 15 اي( (microRNA 15aومرض السكري من النوع الثاني وإمكانية كونها علامة بيولوجية لمرض السكري من النوع الثاني. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Type 2 diabetes |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | مرض السكري من النوع 2 |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | biomarkers for type 2 diabetes mellitus |
| -- | micro-RNA 15a |
| -- | prediabetes |
| -- | type 2 diabetes mellitus |
| -- | المؤشرات الحيوية لداء السكري من النوع الثاني |
| -- | الحمض النووي الريبي الميكروي 15أ |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noha Taha Abd-Elraheem |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rasha Sobh Mohamed Farag |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noran Atef Elkordy |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Amal Ahmed Mohamed |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Noha Taha Abd-Elraheem |
| -- | Rasha Sobh Mohamed Farag |
| -- | Noran Atef Elkordy |
| -- | Amal Ahmed Mohamed |
| Universities | Cairo University |
| Faculties | Faculty of Medicine |
| Department | Department of Internal Medicine |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 11.12.2025 | 92760 | Cai01.11.18.Ph.D.2025.Sa.s | 01010110092760000 | 11.12.2025 | 11.12.2025 | Thesis |